この記事を読む

EGFR遺伝子変異陽性の術後補助化学療法の層別化

Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small C…

この記事を読む

腫瘍サイズと免疫チェックポイント阻害薬

The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with …

この記事を読む

EGFR遺伝子変異陽性、手術追加の意義は?

Thoracic surgery improved overall survival in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung a…

この記事を読む

非扁平上皮癌の方がPD-L1発現とOSが相関しやすい?

Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Non…

この記事を読む

いわゆるオリゴメタに対する外科治療

The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cance…

この記事を読む

抗がん剤+デノスマブ、統合解析でも有効集団見いだせず

Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line c…

この記事を読む

術後補助化学療法としてのゲフィチニブ

Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-S…

この記事を読む

アファチニブ導入を低用量から行っても遜色ない効果

A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small…

この記事を読む

問題点あるがTPS≧50%に対するペムブロリズマブ単剤

Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥50%) NSCLC: Real-world Results with Special Foc…

この記事を読む

再発中皮腫に対するニボルマブ

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, random…